rly-4008
relay therapeutics
['rly-4008', 'bcsm']
exciting data from refocus in small numbers for fgfr2 inhibition in cholangiocarcinoma with rly-4008. orr: 73% with nearly 1 year duration of response in fgfr inhibitor-naive pts with fusions. #asco23 #hpbcsm #cancerresearch 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own